Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.

Abstract	Clinical assessment of the response to antiangiogenic therapy has been cumbersome. A study in this issue of Cancer Cell demonstrates that a combination of magnetic resonance imaging (MRI) for quantification of normalized vessels with measurements of circulating levels of proangiogenic factors, including FGF2, SDF1, and viable circulating endothelial cells, provides an effective means to evaluate the response of recurrent glioblastoma to a prototypical pan-VEGF receptor tyrosine kinase inhibitor, AZD2171.
Authors	Adília Hormigo, Philip H Gutin, Shahin Rafii
Journal	Cancer cell (Cancer Cell) Vol. 11 Issue 1 Pg. 6-8 (Jan 2007) ISSN: 1535-6108 [Print] United States
PMID	17222788 (Publication Type: Comment, Journal Article, Review)
Chemical References	Angiogenesis Inhibitors Antineoplastic Agents Biomarkers, Tumor Quinazolines cediranib
Topics	Angiogenesis Inhibitors (therapeutic use) Animals Antineoplastic Agents (therapeutic use) Biomarkers, Tumor (analysis) Brain Neoplasms (blood supply, drug therapy) Humans Magnetic Resonance Imaging Neovascularization, Pathologic (drug therapy) Quinazolines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!